论文部分内容阅读
乳腺癌是女性的好发肿瘤,占女性所有肿瘤的7%~10%[1]。目前随着乳腺癌综合治疗方法的逐步发展,雌激素受体(ER)阳性的患者已从辅助治疗中明显获益。有研究表明,采取促黄体生成素释放激素(LHRH)类似物进行治疗能够显著改善乳腺癌复发率与转移率,而戈舍瑞林则是目前最受关注的一类LHRH类似物[2]。LHRH是下丘脑分泌的肽类激素,与垂体的LHRH受体结合,促进垂体促性腺细胞合成并分泌卵泡刺激素(FSH)和黄体生
Breast cancer is a good hair tumor in women, accounting for 7% to 10% of all women with cancer [1]. Currently with the progressive development of comprehensive treatment of breast cancer, estrogen receptor (ER) -positive patients have significantly benefited from adjuvant therapy. Some studies have shown that the treatment with luteinizing hormone-releasing hormone (LHRH) analogues can significantly improve the recurrence rate and metastatic rate of breast cancer, while goserelin is the most frequently observed class of LHRH analogues [2]. LHRH is a peptide hormone secreted by the hypothalamus that binds to the pituitary LHRH receptor and promotes pituitary gonadocyte synthesis and secretion of follicle stimulating hormone (FSH) and luteinizing